Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance, and ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer, currently trading at $23 and maintaining a strong 7.48% dividend yield, has entered into an agreement with 3SBio to acquire a VEGFxPD-1 bispecific, known as SSGJ-707, for an upfront ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Value investors rely on traditional forms of analysis on key valuation ... value stocks on the market today. One stock to keep an eye on is Pfizer (PFE). PFE is currently sporting a Zacks Rank ...

Common use cases of AI in the supply chain illustrate the benefits for companies of integrating AI into their operations.

This is where InvestingPro’s powerful stock screener comes in. Among its many pre-built tools, the “ Cash is King ” screener stands out for investors who prioritize financial strength. It identifies ...